Skip to content

Monitoring Obese Patients : Impact on the Frequency of Monitoring Weight

Monitoring Obese Patients: Impact on the Frequency of Monitoring Weight, Quality of Life, Dietary Behavior, Physical Ability and Comorbidities

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02374866
Acronym
SUIVIOBESITE
Enrollment
96
Registered
2015-03-02
Start date
2015-03-31
Completion date
2016-07-31
Last updated
2016-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity, Obesity, Quality of Life

Keywords

Obesity, Morbid Obesity, Therapeutic education

Brief summary

The literature data show that long-term monitoring has an effect on weight loss, comorbidity and on improving the quality of life. However, there are still no studies on monitoring obese patients after taking initial multidisciplinary approach. The recommendations of the HAS 2011 advocated continuous monitoring needed to prevent weight regain, monitor the consequences of overweight and treat comorbidities. This requires a long-term support. The frequency of follow-up consultations is not specified and must be adapted to achieve a weight loss target and maintain. Having no specific recommendations on the frequency of monitoring, the investigators chose to experiment closer monitoring than our current monitoring to assess what is the best frequency monitoring, in terms of: weight loss, quality of life, feeding behavior, changes in physical abilities, evolution of comorbidities associated with obesity. The recommendations of the HAS 2011 advocate support of a multidisciplinary obesity for weight loss of 5% to 10 %, which, if maintained, can reduce comorbidities associated with obesity (type 2 diabetes, hypertension, pain associated with osteoarthritis).

Detailed description

2 groups of randomized patients will be followed: * The control group will follow the current center: every four months for a year, combined with monitoring by email or regular mail during the year. * The experimental group will be a follow-up every two months for one year HDJ more of the same followed by email or postal mail. Follow by email or mail is identical to the control group, as well as HDJ 12 months.

Interventions

OTHERcloser monitoring

Sponsors

University Hospital, Limoges
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* \- Age ≥ 18 - ≤ 75 years * Obesity with a BMI ≥ 35 or ≥ 30 if associated with at least one comorbidity whose support was commenced or continued during the initial hospitalization. * Patients hospitalized for a period of at least 3 weeks in the Bernard Descottes center and were supported on dietary, psychological, psychomotor and physical education in a therapeutic approach. * Patients who have signed consent form. * Patients who never underwent bariatric surgery and bariatric surgery have not seen in the year following their hospitalization in Bernard Descottes Center. * Patient accepting the constraints of the protocol in case of close monitoring. * Patients able to travel with their own vehicle to Bernard Descottes Center. * Affiliate or beneficiary of a social security scheme

Exclusion criteria

* \- Patients who have hospitalized in Bernard Descottes Center. * Failure to follow the protocol because of insufficient command of French or concomitant illness. * Pregnant or breastfeeding. * Patients under guardianship or under judicial protection. * Participation to another trial which can impact on patient's experimental disease during all the study, and patients who are in an exclusion period of another trial.

Design outcomes

Primary

MeasureTime frame
percentage of weight loss at 12 months1 year
percentage of change in BMI at 12 months1 year

Secondary

MeasureTime frame
Change of waist at 12 months1 year
Changes in body composition1 year
Change of quality of life at 12 months1 year
Change of medication at 12 months1 year

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026